CIMA, Gene therapy and Hepatology Unit, University of Navarra, Pamplona, Navarra, Spain.
Departamento de Bioquímica y Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain.
J Immunother Cancer. 2013 May 29;1:3. doi: 10.1186/2051-1426-1-3. eCollection 2013.
Treatment with agonist anti-CD137 (4-1BB) immunostimulatory monoclonal antibodies elicits complete tumor regressions in a number of transplanted hematological and solid malignancies in mice. Rejection is mainly dependent on cytotoxic T lymphocytes (CTL) and IFNγ, although a role for NK cells and dendritic cells has been observed in some tumor models. Rejection of EG7-derived thymomas has been shown to be CTL-dependent but not NK-dependent.
In this therapeutic setting, we show that both the perforin-granzyme and FasL effector systems are readily expressed by CD8(+) T lymphocytes infiltrating the EG7 lymphomas which are undergoing rejection. Using knock-out mice, we demonstrate that both effector cytolytic systems are involved in the execution of complete immune rejections against EG7 established tumors. In accordance, EG7 tumor cells were susceptible in vitro to both killing mechanisms acting in a synergistic fashion.
CD137-elicited rejection of EG7-derived tumors involves the interplay of at least two final effector cytolytic mechanisms that act in cooperation.
在一些移植的血液学和实体恶性肿瘤的小鼠模型中,激动剂抗 CD137(4-1BB)免疫刺激单克隆抗体的治疗引发了完全的肿瘤消退。排斥反应主要依赖于细胞毒性 T 淋巴细胞(CTL)和 IFNγ,尽管在一些肿瘤模型中已经观察到 NK 细胞和树突状细胞的作用。已经表明,EG7 衍生的胸腺瘤的排斥反应依赖于 CTL,而不依赖于 NK。
在这种治疗环境中,我们表明,浸润正在发生排斥反应的 EG7 淋巴瘤的 CD8+T 淋巴细胞容易表达穿孔素-颗粒酶和 FasL 效应系统。使用敲除小鼠,我们证明了这两种效应细胞溶解系统都参与了针对 EG7 建立的肿瘤的完全免疫排斥反应的执行。相应地,EG7 肿瘤细胞在体外易受到两种协同作用的杀伤机制的影响。
CD137 引发的 EG7 衍生肿瘤的排斥反应涉及至少两种最终的协同作用的效应细胞溶解机制的相互作用。